ASMB (Assembly Biosciences) Earnings per share growth rate in current year

ASMB (Assembly Biosciences) - company brandmark

Assembly Biosciences optimizes the synthesis of trial batches through a network of external laboratories, ensuring supply flexibility. The company's revenues are based on the development of advanced therapies for chronic hepatitis B. The YoY EPS volatility reflects the earnings per share dynamics, where the latest value is recorded as -10.40. Analysis of this trend confirms expansion into global hepatology through innovative capsid inhibitors.

ASMB (Assembly Biosciences, Inc.) Earnings growth in current year history from 07/04/2022 to 11/10/2026

Analytical breakdowns and data insights for company Assembly Biosciences (ASMB)

- share price and consensus valuation forecast:
Price Chart Assembly Bio|ASMB - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Assembly Corp|ASMB - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Assembly Biosciences|ASMB - Book Capitalization|Market Capitalization to Book Value Ratio assemblybio.com|ASMB - Aggregate Company Assets
- debt and liquidity details:
Total Debt to Capital Coefficient Assembly Biosciences|ASMB - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient assemblybio.com|ASMB - Company Aggregate Debts|Debts to Book Value Assembly Corp|ASMB - Company Long-Term Debt|Company Current Liabilities Assembly Biosciences|Quick Liquidity assemblybio.com
- net income and valuation multiples indicators:
ASMB - Company Net Income|Expected Profit Assembly Biosciences|ASMB - Price to Earnings Ratio|Projected Price to Earnings Ratio Assembly Corp|ASMB - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Assembly Corp|ASMB - Operating profit EBITDA|Earnings per share for the last twelve months Assembly Biosciences|ASMB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months assemblybio.com|ASMB - Earnings per share growth in current year|Expected net earnings per share growth next year Assembly Biosciences
Fundamental valuation:ASMB Assembly Bio
Mass-produced product of Assembly Biosciences, Inc.

For an investor in Assembly Biosciences (ASMB), controlling R&D cost efficiency is critical given the heavy reliance on external contractors (CRO/CMO). This metric measures the annual dynamics of net earnings per share, reflecting the actual return on capital over a cycle. By analyzing the annual EPS growth trend, one can identify stagnation phases or the risk of capital being frozen during periods of sideways price action.

Main competitors

ARWR (Arrowhead Pharma) - Earnings per share growth in current year|MIRM (Mirum Pharma) - Earnings growth in current year|Earnings per share growth rate in current year dynavax.com DVAX|Earnings per share growth in current year Arbutus Biopharma (ABUS)|IVA (inventivapharma.com) - Earnings per share increase in current year|Earnings growth in current year GYRE (Gyre Therapeutics)|Earnings growth in current year Galectin Therapeutics, Inc. GALT|GNFT - Earnings per share growth in current year|Expected net earnings per share growth this year DURECT Corporation DRRX|aligos.com (ALGS) - Earnings per share growth in current year|BIVI - Expected net earnings per share growth this year|GLMD (Galmed Pharmaceuticals Ltd) - Earnings growth in current year|Earnings per share growth rate in current year ENDRA Life Sciences Inc NDRA|Earnings per share growth in current year Hepion Pharmaceuticals (HEPA)